May 18 2010
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow System, the first rapid and easy-to-use diagnostic system for measuring platelet reactivity to multiple antiplatelet agents, announced today that the company has signed a new agreement with Medico's Hirata for distribution of its VerifyNow System in Japan.
The VerifyNow System helps physicians assess patients' response to all major antiplatelet therapies such as aspirin, Ticlid®, Plavix®, Effient® and GP IIb/IIIa inhibitors. As response to these drugs varies, the tests help physicians ensure their patients on antiplatelet therapies are receiving the optimal benefit.
"Partnering with Medico's Hirata, one of the largest medical device distributors in Japan, is an integral element of our international expansion strategy," said Timothy I. Still, President and CEO of Accumetrics.
"With our 90-strong direct sales organization, coupled with a large distribution network and experienced marketing and regulatory teams, we are well-positioned to bring personalized antiplatelet testing to Japan's physicians," said Masataka Hirata, President of Medico's Hirata.
New Alzheimer's guidelines focus on risk, not diagnosis, in healthy adults